ELI LILLY AND COMPANY Deferred Tax Assets, Deferred Income
ELI LILLY AND COMPANY (LLY) had Deferred Tax Assets, Deferred Income of $76.50 million as of 2013-12-31, per its 10-K filed 2014-02-19.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2014-02-19
- 2013-12-31: Deferred Tax Assets, Deferred Income $76.50M.
- 2012-12-31: Deferred Tax Assets, Deferred Income $278.60M.
- 2011-12-31: Deferred Tax Assets, Deferred Income $207.10M.
- 2010-12-31: Deferred Tax Assets, Deferred Income $112.80M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2013-12-31 | $76.50M 10-K · filed 2014-02-19 |
| 2012-12-31 | $278.60M 10-K · filed 2014-02-19 |
| 2011-12-31 | $207.10M 10-K · filed 2013-02-21 |
| 2010-12-31 | $112.80M 10-K · filed 2012-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |